دورية أكاديمية
أعرض في EDS

Susceptibility to Pentylenetetrazole-Induced Seizures in Mice with Distinct Activity of the Endogenous Opioid System.

التفاصيل البيبلوغرافية
العنوان: Susceptibility to Pentylenetetrazole-Induced Seizures in Mice with Distinct Activity of the Endogenous Opioid System.
المؤلفون: Ruszczak A; Department of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 166, 02-787 Warsaw, Poland., Poznański P; Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, 05-552 Jastrzębiec, Poland.; Laboratory of Host-Microbiota Interactions, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteura 3, 02-093 Warsaw, Poland., Leśniak A; Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-697 Warsaw, Poland., Łazarczyk M; Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, 05-552 Jastrzębiec, Poland., Skiba D; Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, 05-552 Jastrzębiec, Poland., Nawrocka A; Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, 05-552 Jastrzębiec, Poland., Gaweł K; Department of Experimental and Clinical Pharmacology, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland., Paszkiewicz J; Department of Health, John Paul II University of Applied Sciences in Biala Podlaska, Sidorska 95/97, 21-500 Biała Podlaska, Poland., Mickael ME; Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, 05-552 Jastrzębiec, Poland., Sacharczuk M; Department of Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, 05-552 Jastrzębiec, Poland.; Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-697 Warsaw, Poland.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 26; Vol. 25 (13). Date of Electronic Publication: 2024 Jun 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Pentylenetetrazole*/toxicity , Seizures*/metabolism , Seizures*/drug therapy , Seizures*/chemically induced, Animals ; Mice ; Male ; Naloxone/pharmacology ; Disease Models, Animal ; Diazepam/pharmacology ; Disease Susceptibility ; Anticonvulsants/pharmacology ; Anticonvulsants/therapeutic use ; Narcotic Antagonists/pharmacology
مستخلص: Currently, pharmacotherapy provides successful seizure control in around 70% of patients with epilepsy; however, around 30% of cases are still resistant to available treatment. Therefore, effective anti-epileptic therapy still remains a challenge. In our study, we utilized two mouse lines selected for low (LA) and high (HA) endogenous opioid system activity to investigate the relationship between down- or upregulation of the opioid system and susceptibility to seizures. Pentylenetetrazole (PTZ) is a compound commonly used for kindling of generalized tonic-clonic convulsions in animal models. Our experiments revealed that in the LA mice, PTZ produced seizures of greater intensity and shorter latency than in HA mice. This observation suggests that proper opioid system tone is crucial for preventing the onset of generalized tonic-clonic seizures. Moreover, a combination of an opioid receptor antagonist-naloxone-and a GABA receptor agonist-diazepam (DZP)-facilitates a significant DZP-sparing effect. This is particularly important for the pharmacotherapy of neurological patients, since benzodiazepines display high addiction risk. In conclusion, our study shows a meaningful, protective role of the endogenous opioid system in the prevention of epileptic seizures and that disturbances in that balance may facilitate seizure occurrence.
References: Neuropeptides. 2013 Dec;47(6):467-75. (PMID: 24210141)
Brain Res. 1980 Oct 6;198(2):323-32. (PMID: 6250670)
Epilepsia. 2012 Nov;53(11):1860-7. (PMID: 22708847)
Brain Sci. 2021 May 13;11(5):. (PMID: 34067974)
Psychopharmacology (Berl). 1994 Jul;115(3):311-9. (PMID: 7871070)
Front Mol Neurosci. 2018 Sep 25;11:351. (PMID: 30319356)
Epilepsia. 2017 Apr;58(4):512-521. (PMID: 28276062)
Front Neural Circuits. 2013 Sep 18;7:142. (PMID: 24065890)
Neuropharmacology. 2019 Jan;144:37-42. (PMID: 30326238)
Neuropharmacology. 2016 Feb;101:506-18. (PMID: 26474659)
Neuropharmacology. 2007 Mar;52(3):895-903. (PMID: 17126860)
Epilepsia Open. 2021 Sep;6(3):528-538. (PMID: 34664432)
Brain. 2007 Apr;130(Pt 4):1009-16. (PMID: 17301080)
Anesthesiology. 2009 Dec;111(6):1327-33. (PMID: 19934879)
Mol Neurobiol. 2014 Oct;50(2):626-46. (PMID: 24705860)
Physiol Behav. 2001 Feb;72(3):421-6. (PMID: 11274687)
Cold Spring Harb Perspect Med. 2015 Jun 01;5(6):. (PMID: 26033084)
Neuropharmacology. 2017 May 15;118:90-101. (PMID: 28322978)
J Pharmacol Exp Ther. 2006 Jun;317(3):1337-48. (PMID: 16537798)
Psychopharmacology (Berl). 1991;103(3):380-3. (PMID: 1647539)
Eur J Pharmacol. 1978 Jan 1;47(1):19-27. (PMID: 618728)
Neuroscience. 2004;129(3):733-42. (PMID: 15541894)
Br J Pharmacol. 2010 Sep;161(2):384-92. (PMID: 20735422)
Neurosci Lett. 2010 Nov 19;485(2):125-8. (PMID: 20816918)
Brain. 2007 Apr;130(Pt 4):1017-28. (PMID: 17347252)
Neuroscience. 2009 Sep 29;163(1):490-9. (PMID: 19345722)
Curr Neuropharmacol. 2004 Oct;2(4):395-402. (PMID: 18997874)
Neurochem Int. 1999 May;34(5):435-45. (PMID: 10397372)
Anesth Analg. 2007 Dec;105(6):1729-35, table of contents. (PMID: 18042875)
Neurochem Int. 2003 Dec;43(7):629-37. (PMID: 12892650)
Epilepsia. 2010 Mar;51(3):344-53. (PMID: 19674055)
PLoS One. 2014 Sep 15;9(9):e107399. (PMID: 25221944)
Brain Res. 1983 Oct;287(2):197-210. (PMID: 6315187)
Epilepsia. 2013 Aug;54 Suppl 4:13-23. (PMID: 23909850)
Clin Toxicol (Phila). 2018 Aug;56(8):737-743. (PMID: 29148295)
Handb Exp Pharmacol. 2017;239:363-378. (PMID: 28204957)
Nat Rev Neurosci. 2018 Aug;19(8):499-514. (PMID: 29934561)
Pharmacol Rep. 2012;64(3):576-85. (PMID: 22814011)
Brain Res Bull. 2005 May 30;65(6):495-9. (PMID: 15862921)
Brain. 2006 Mar;129(Pt 3):642-54. (PMID: 16399805)
Epilepsy Res. 2013 Sep;106(1-2):54-63. (PMID: 23619005)
J Pharmacol Exp Ther. 1985 Feb;232(2):439-44. (PMID: 2982011)
Behav Brain Funct. 2021 May 29;17(1):5. (PMID: 34051813)
J Pharmacol Exp Ther. 2002 Nov;303(2):723-9. (PMID: 12388657)
Anesth Analg. 2000 Jul;91(1):185-91. (PMID: 10866910)
Front Neurosci. 2022 Apr 28;16:864514. (PMID: 35573314)
Nature. 1997 Dec 11;390(6660):611-4. (PMID: 9403690)
Neurochem Res. 2011 Nov;36(11):2091-5. (PMID: 21842273)
Neuroscience. 2009 Jun 16;161(1):301-10. (PMID: 19303919)
Hum Mol Genet. 2015 Aug 1;24(15):4306-16. (PMID: 25941323)
Am J Surg Pathol. 2007 Feb;31(2):322-5. (PMID: 17255780)
Prog Brain Res. 2002;135:3-11. (PMID: 12143350)
Hippocampus. 2011 Sep;21(9):1010-20. (PMID: 21391243)
Br J Pharmacol. 1999 May;127(1):275-83. (PMID: 10369483)
Hippocampus. 2009 Nov;19(11):1051-4. (PMID: 19437412)
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:126-31. (PMID: 22918032)
Brain Res. 1995 Feb 20;672(1-2):42-7. (PMID: 7749752)
Psychopharmacology (Berl). 1980;67(3):211-4. (PMID: 6770398)
Acta Neurobiol Exp (Wars). 2014;74(1):26-32. (PMID: 24718041)
Clin Pharmacol Ther. 1994 May;55(5):569-80. (PMID: 8181201)
Brain Res. 1986 Nov 5;397(1):156-60. (PMID: 3801860)
J Pharmacol Exp Ther. 1987 Feb;240(2):571-7. (PMID: 3027318)
Epilepsy Res. 2002 Jun;50(1-2):105-23. (PMID: 12151122)
Cell Cycle. 2019 Jan;18(2):226-237. (PMID: 30595095)
J Forensic Sci. 2003 May;48(3):683-6. (PMID: 12762549)
Front Mol Neurosci. 2017 Aug 07;10:245. (PMID: 28824375)
Nat Prod Rep. 2011 Apr;28(4):741-62. (PMID: 21340067)
J Pharmacol Exp Ther. 2008 May;325(2):500-6. (PMID: 18292293)
Prog Neurobiol. 1996 Dec;50(5-6):557-83. (PMID: 9015827)
Behav Brain Res. 2015 Feb 1;278:429-34. (PMID: 25447299)
Brain Sci. 2023 May 25;13(6):. (PMID: 37371338)
Neurology. 1996 Apr;46(4):1170-1. (PMID: 8780117)
BMC Biol. 2009 Aug 26;7:55. (PMID: 19709398)
Epilepsia. 2018 Jun;59(6):1148-1153. (PMID: 29741207)
Brain Res. 1990 May 28;517(1-2):236-44. (PMID: 2165433)
Eur J Pharmacol. 1996 Mar 28;299(1-3):41-5. (PMID: 8901006)
فهرسة مساهمة: Keywords: endogenous opioid system; epilepsy; seizures
المشرفين على المادة: WM5Z385K7T (Pentylenetetrazole)
36B82AMQ7N (Naloxone)
Q3JTX2Q7TU (Diazepam)
0 (Anticonvulsants)
0 (Narcotic Antagonists)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715
رمز التحديث: 20240715
مُعرف محوري في PubMed: PMC11241619
DOI: 10.3390/ijms25136978
PMID: 39000086
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25136978